<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "5: principally from costs incurred", fill: "#900"},
{source: "5: principally from costs incurred", target: "5: development", fill: "#900"},
{source: "5: development", target: "5: technologies", fill: "#900"},
{source: "5: technologies", target: "5: administrative expenses", fill: "#900"},
{source: "5: administrative expenses", target: "5: prosecution", fill: "#900"},
{source: "5: prosecution", target: "5: patent applications", fill: "#900"},
{source: "5: principally from costs incurred", target: "6: incur significant", fill: "#414a4c"},
{source: "6: incur significant", target: "6: losses at least until", fill: "#414a4c"},
{source: "6: losses at least until", target: "6: primarily owing", fill: "#414a4c"},
{source: "6: primarily owing", target: "6: development programs", fill: "#414a4c"},
{source: "6: development programs", target: "6: preclinical studies", fill: "#414a4c"},
{source: "6: preclinical studies", target: "6: clinical trials", fill: "#414a4c"},
{source: "6: clinical trials", target: "6: establishment", fill: "#414a4c"},
{source: "6: establishment", target: "6: distribution capabilities necessary", fill: "#414a4c"},
{source: "6: distribution capabilities necessary", target: "6: support commercialization efforts", fill: "#414a4c"},
{source: "6: incur significant", target: "8: things on successfully", fill: "#20b2aa"},
{source: "8: things on successfully", target: "8: development", fill: "#20b2aa"},
{source: "8: development", target: "8: product candidates", fill: "#20b2aa"},
{source: "8: product candidates", target: "8: regulatory approvals", fill: "#20b2aa"},
{source: "8: regulatory approvals", target: "8: establishing manufacturing sales", fill: "#20b2aa"},
{source: "8: establishing manufacturing sales", target: "8: marketing arrangements with third", fill: "#20b2aa"},
{source: "8: marketing arrangements with third", target: "8: key manufacturing components", fill: "#20b2aa"},
{source: "8: key manufacturing components", target: "8: sufficient cash", fill: "#20b2aa"},
{source: "8: sufficient cash", target: "8: activities", fill: "#20b2aa"},
{source: "8: things on successfully", target: "START_HERE", fill: "#20b2aa"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palantir_Technologies">Palantir Technologies</a></td>
      <td>Palantir Technologies is a public American software company that specializes in big data analytics. Headquartered in Denver, Colorado, it was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Agilent_Technologies">Agilent Technologies</a></td>
      <td>Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_Trials_Directive">Clinical Trials Directive</a></td>
      <td>The Clinical Trials Directive (Officially Directive 2001/20/EC of 4 April 2001, of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use) is a European Union directive that aimed at facilitating the internal market in medicinal products within the European Union, while at the same time maintaining an appropriate level of protection for public health. It seeks to simplify and harmonise the administrative provisions governing clinical trials in the European Community, by establishing a clear, transparent procedure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>AASTROM BIOSCIENCES INC      Item 1A   <font color="blue">Risk Factors </font>      Our  business is subject to a number of <font color="blue">uncertainties</font>, including those     discussed below</td>
    </tr>
    <tr>
      <td>Our <font color="blue">past losses</font> and expected <font color="blue">future losses</font> cast doubt on our ability to     operate profitably</td>
    </tr>
    <tr>
      <td>We were <font color="blue">incorporated</font> in 1989 and have experienced substantial operating     <font color="blue">losses since inception</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of June </font>30, 2006, we have incurred a cumulative     net loss totaling approximately dlra141 million</td>
    </tr>
    <tr>
      <td>These losses have resulted     <font color="blue">principally from costs incurred</font> in the research and <font color="blue">development</font> of our cell     culture  <font color="blue">technologies</font>  and  the  AastromReplicell  System, general and     <font color="blue">administrative expenses</font>, and the <font color="blue">prosecution</font> of <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font></td>
    </tr>
    <tr>
      <td>We     expect to <font color="blue">incur <font color="blue">significant</font></font> operating <font color="blue">losses at least until</font>, and probably     after,  product  sales  increase,  <font color="blue">primarily owing</font> to our research and     <font color="blue">development</font> programs, including pre-clinical studies and <font color="blue"><font color="blue">clinical trial</font>s</font>,     and the <font color="blue">establishment</font> of marketing and <font color="blue"><font color="blue">distribution</font> <font color="blue">capabilities</font> <font color="blue">necessary</font></font>     to <font color="blue">support <font color="blue">commercialization</font> efforts</font> for our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font>     with any <font color="blue">certainty</font> the amount of <font color="blue">future losses</font></td>
    </tr>
    <tr>
      <td>Our ability to achieve     profitability will depend, among other things, on <font color="blue">successfully</font> completing     the <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font>, obtaining <font color="blue"><font color="blue">regulatory</font> approvals</font>,     <font color="blue">establishing</font> <font color="blue">manufacturing</font>, sales and <font color="blue">marketing <font color="blue">arrangements</font> with third</font>     parties, maintaining supplies of <font color="blue">key <font color="blue">manufacturing</font> <font color="blue">components</font></font>, and raising     <font color="blue">sufficient cash</font> to fund our operating <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>In addition, we may not be     able to achieve or <font color="blue">sustain profitability</font></td>
    </tr>
    <tr>
      <td>Failure to obtain and maintain required <font color="blue"><font color="blue">regulatory</font> approvals</font> would severely     limit our ability to sell our products</td>
    </tr>
    <tr>
      <td>We must obtain the approval of the FDA before <font color="blue">commercial sales</font> of our cell     product  <font color="blue">candidates</font>  may  commence  in the US, which we believe will     ultimately be the <font color="blue">largest market</font> for our products</td>
    </tr>
    <tr>
      <td>We will also be required     to obtain <font color="blue">additional</font> approvals from various foreign <font color="blue">regulatory</font> <font color="blue">authorities</font>     to initiate sales <font color="blue">activities</font> of <font color="blue"><font color="blue">cell product</font>s</font> in those jurisdictions, such     as the EU If we <font color="blue">cannot demonstrate</font> the safety, re<font color="blue">liability</font> and efficacy of     our  cell  product  <font color="blue">candidates</font>, or of the cells produced in our device     products, we may not be able to obtain required <font color="blue"><font color="blue">regulatory</font> approvals</font></td>
    </tr>
    <tr>
      <td>If we     <font color="blue">cannot demonstrate</font> the safety and efficacy of our <font color="blue">technologies</font> and product     <font color="blue">candidates</font>, or if one or more patients die or <font color="blue">suffer severe complications</font>,     the FDA or other <font color="blue">regulatory</font> <font color="blue">authorities</font> could delay or withhold <font color="blue">regulatory</font>     approval of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Finally, even if we obtain <font color="blue">regulatory</font> approval of a product, that approval     may be subject to <font color="blue">limitations on</font> the <font color="blue">indicated uses</font> for which it may be     marketed</td>
    </tr>
    <tr>
      <td>Even after granting <font color="blue">regulatory</font> approval, the FDA and <font color="blue">regulatory</font>     agencies  in  other  countries continue to review and inspect marketed     products, <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> and <font color="blue">manufacturing</font> <font color="blue">facilities</font>, which may create     <font color="blue">additional</font>  <font color="blue">regulatory</font>  burdens</td>
    </tr>
    <tr>
      <td>Later <font color="blue">discovery</font> of <font color="blue">previously unknown</font>     problems  with  a  product,  <font color="blue"><font color="blue">manufacture</font>r</font>  or  facility, may result in     <font color="blue"><font color="blue">restrictions</font> on</font> the product or <font color="blue"><font color="blue">manufacture</font>r</font>, including a withdrawal of the     product  from  the  market</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">regulatory</font> agencies may establish     <font color="blue">additional</font> regulations that <font color="blue">could prevent</font> or delay <font color="blue">regulatory</font> approval of     our products</td>
    </tr>
    <tr>
      <td>Any changes in the <font color="blue">government</font>al <font color="blue">regulatory</font> classifications of our products     <font color="blue">could prevent</font>, limit or delay our ability to market or develop our products</td>
    </tr>
    <tr>
      <td>The FDA establishes <font color="blue">regulatory</font> <font color="blue">requirements</font> based on the classification of a     product</td>
    </tr>
    <tr>
      <td>Because our product <font color="blue">development</font> programs are designed to satisfy     the <font color="blue">standards applicable</font> to <font color="blue">biological licensure</font> for our <font color="blue">cellular products</font>,     any change in the <font color="blue">regulatory</font> classification or <font color="blue">designation would affect</font> our     ability to obtain FDA approval of our products</td>
    </tr>
    <tr>
      <td>The AastromReplicell System     is used to produce <font color="blue">different <font color="blue">cell mixtures</font></font>, and each of these <font color="blue">cell mixtures</font>     (such as our TRCs) is, under current regulations, regulated as a biologic     product, which requires a BLA       New EU Directives (laws) have <font color="blue">become <font color="blue">effective</font></font>, and have influenced the     <font color="blue">requirements</font> for <font color="blue">manufacturing</font> <font color="blue"><font color="blue">cell product</font>s</font> and the conduct of clinical     trials</td>
    </tr>
    <tr>
      <td>These changes have delayed or in some <font color="blue">cases temporarily halted</font>     <font color="blue"><font color="blue">clinical trial</font>s</font> of <font color="blue">cellular products</font> in the EU Recent changes and annexes     to  the  European  Union  Medicinal  Products  Prime Directive shifted     patient-derived cells to the <font color="blue">medicinal products</font> category, <font color="blue">which will</font> require     MA(s)  in order to market and sell these products</td>
    </tr>
    <tr>
      <td>These new laws have     delayed some of our current planned <font color="blue"><font color="blue">clinical trial</font>s</font> with TRCs in the EU, and     will require <font color="blue"><font color="blue">clinical trial</font>s</font> with data submission and review by one or more     European <font color="blue">regulatory</font> bodies</td>
    </tr>
    <tr>
      <td>There is un<font color="blue">certainty</font> about which <font color="blue">clinical trial</font>     <font color="blue">activities</font> and data are required, and because of the recent                                         15       _________________________________________________________________    [65]Table of <font color="blue">Contents       </font>nature  of  these  new  <font color="blue">directives</font>,  laws and regulations, there is no     <font color="blue">established precedent</font> to understand the timeline or other <font color="blue">requirements</font> for     MA       Our <font color="blue">inability</font> to complete our product <font color="blue">development</font> <font color="blue">activities</font> <font color="blue">successfully</font>     <font color="blue">would severely limit</font> our ability to operate or <font color="blue">finance <font color="blue">operations</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Commercialization in the US and the EU </font>of our cell <font color="blue">product <font color="blue">candidates</font></font> will     require <font color="blue">completion</font> of substantial <font color="blue"><font color="blue">clinical trial</font>s</font>, and obtaining sufficient     safety and efficacy results to support required <font color="blue">registration</font> approval and     market <font color="blue">acceptance</font> of our cell <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We may not be able to     <font color="blue">successfully</font>  complete  the  <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font>, or     <font color="blue">successfully</font> market our <font color="blue">technologies</font> or <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We, and any of     our potential collaborators, may encounter problems and delays relating to     research and <font color="blue">development</font>, <font color="blue">regulatory</font> approval and <font color="blue">intellectual property</font>     rights  of  our  <font color="blue">technologies</font> and <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Our research and     <font color="blue">development</font>  programs  may  not  be  successful,  and our <font color="blue">cell culture</font>     <font color="blue">technologies</font> and <font color="blue">product <font color="blue">candidates</font></font> may not <font color="blue">facilitate</font> the production of     <font color="blue">cells outside</font> the human body with the expected result</td>
    </tr>
    <tr>
      <td>Our <font color="blue">technologies</font> and     cell <font color="blue">product <font color="blue">candidates</font></font> may not prove to be safe and <font color="blue">efficacious</font> in clinical     trials, and we may not obtain the requisite <font color="blue"><font color="blue">regulatory</font> approvals</font> for our     <font color="blue">technologies</font> or <font color="blue">product <font color="blue">candidates</font></font> and the cells produced in <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>If any of these events occur, we may not have <font color="blue">adequate resources</font> to continue     <font color="blue">operations</font>  for  the  period  required  to  resolve the issue delaying     <font color="blue">commercialization</font> and we may not be able to <font color="blue">raise capital</font> to finance our     <font color="blue">continued operation during</font> the period required for resolution of that issue</td>
    </tr>
    <tr>
      <td>We must <font color="blue">successfully</font> complete our <font color="blue"><font color="blue">clinical trial</font>s</font> to be able to market     certain of our products</td>
    </tr>
    <tr>
      <td>To be able to <font color="blue">market <font color="blue">therapeutic</font> <font color="blue"><font color="blue">cell product</font>s</font></font> in the US and in the EU, we     must demonstrate, through extensive <font color="blue">preclinical studies</font> and <font color="blue"><font color="blue">clinical trial</font>s</font>,     the safety and efficacy of our processes and <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If our     <font color="blue"><font color="blue">clinical trial</font>s</font> are not successful, our <font color="blue">products may</font> not be marketable</td>
    </tr>
    <tr>
      <td>Our ability to complete our <font color="blue"><font color="blue">clinical trial</font>s</font> in a <font color="blue">timely manner depends on</font>     many factors, including the rate of <font color="blue">patient <font color="blue">enrollment</font></font></td>
    </tr>
    <tr>
      <td>Patient <font color="blue">enrollment</font>     can vary with the size of the <font color="blue">patient population</font>, the proximity of suitable     patients to clinical sites, perceptions of the utility of <font color="blue">cell therapy</font> for     the treatment of <font color="blue">certain diseases</font> and the <font color="blue">eligibility criteria</font> for the     study</td>
    </tr>
    <tr>
      <td>We have experienced delays in <font color="blue">patient accrual</font> in our previous and     current <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>If we experience <font color="blue">future delays</font> in <font color="blue">patient accrual</font>,     we could experience <font color="blue">increased costs</font> and <font color="blue">delays associated with clinical</font>     trials, <font color="blue">which would</font> impair our product <font color="blue">development</font> programs and our ability     to  market our products</td>
    </tr>
    <tr>
      <td>Furthermore, the FDA monitors the progress of     <font color="blue"><font color="blue">clinical trial</font>s</font> and it may suspend or terminate <font color="blue"><font color="blue">clinical trial</font>s</font> at any time     due to <font color="blue">patient safety</font> or other <font color="blue">considerations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">research programs</font> are <font color="blue">currently directed at improving</font> TRC <font color="blue">functionality</font>     for  certain  clinical  <font color="blue">indication</font>s, improving product shelf life, and     <font color="blue">decreasing</font> the cost of <font color="blue">manufacturing</font> our TRC products</td>
    </tr>
    <tr>
      <td>These production     process changes may alter the <font color="blue">functionality</font> of our TRCs, and require various     levels of <font color="blue">experimental</font> and clinical testing and <font color="blue">evaluation</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">such testing</font>     could  lengthen  the  time before these <font color="blue">products would</font> be <font color="blue">commercially</font>     available</td>
    </tr>
    <tr>
      <td>Even  if <font color="blue">successful clinical</font> results are reported for a <font color="blue">product from</font> a     completed  <font color="blue">clinical trial</font>, this does not mean that the results will be     sustained  over time, or are sufficient for a marketable or <font color="blue">regulatory</font>     <font color="blue">approvable product</font></td>
    </tr>
    <tr>
      <td>Even  if  we obtain <font color="blue"><font color="blue">regulatory</font> approvals</font> to sell our products, lack of     commercial <font color="blue">acceptance</font> could impair our business</td>
    </tr>
    <tr>
      <td>We will be seeking to obtain <font color="blue"><font color="blue">regulatory</font> approvals</font> to market our TRC cell     products for <font color="blue">tissue repair</font> and <font color="blue">regeneration <font color="blue">treatments</font></font></td>
    </tr>
    <tr>
      <td>Even if we obtain     all required <font color="blue"><font color="blue">regulatory</font> approvals</font>, we cannot be certain that our products     and <font color="blue">processes will</font> be accepted in the market place at a level that would     allow  us  to  operate profitably</td>
    </tr>
    <tr>
      <td>Our TRCs <font color="blue">will <font color="blue">face competition</font> from</font>     existing, and/or potential other <font color="blue">new <font color="blue">treatments</font></font> in the <font color="blue">future which could</font>     <font color="blue">limit revenue potential</font></td>
    </tr>
    <tr>
      <td>It may be <font color="blue">necessary</font> to increase the yield and/or     cell type purity for certain of our AastromReplicell System <font color="blue">cell processes</font>     to gain commercial <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">technologies</font> or <font color="blue">product <font color="blue">candidates</font></font> may     not be employed in all <font color="blue">potential <font color="blue"><font color="blue">application</font>s</font></font> being <font color="blue">investigated</font>, and any     reduction  in  <font color="blue"><font color="blue">application</font>s</font>  would  limit the market <font color="blue">acceptance</font> of our     <font color="blue">technologies</font> and <font color="blue">product <font color="blue">candidates</font></font>, and our <font color="blue">potential revenues</font></td>
    </tr>
    <tr>
      <td>16       _________________________________________________________________    [66]Table of <font color="blue">Contents       </font>The  market  for our <font color="blue">products will</font> be <font color="blue">heavily dependent <font color="blue">on <font color="blue">third party</font></font></font>     <font color="blue"><font color="blue">reimbursement</font> policies</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">successfully</font> <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font> will depend     on the extent to which <font color="blue">government</font> healthcare programs, such as Medicare and     Medicaid,  as  well  as  private  health  insurers, health maintenance     <font color="blue">organizations</font> and other <font color="blue"><font color="blue">third party</font> payors will pay</font> for our products and     related <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font><font color="blue">by <font color="blue">third party</font> payors depends on</font> a number     of factors, including the payor’s determination that use of the product is     safe  and  <font color="blue">effective</font>,  not  <font color="blue">experimental</font> or investigational, medically     <font color="blue">necessary</font>,  <font color="blue">appropriate</font>  for  the <font color="blue">specific patient</font> and cost-<font color="blue">effective</font></td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font>in the US or foreign countries may not be available or     maintained for any of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If we do not obtain approvals     for <font color="blue">adequate <font color="blue">third party</font> <font color="blue">reimbursement</font>s</font>, we may not be able to establish or     maintain <font color="blue">price levels sufficient</font> to realize an <font color="blue">appropriate</font> return on our     <font color="blue">investment</font> in product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">limits on <font color="blue">reimbursement</font> from third</font>     <font color="blue">party payors may reduce</font> the demand for, or <font color="blue">negatively affect</font> the price of,     our products</td>
    </tr>
    <tr>
      <td>For example, in the past, published studies have suggested     that  stem  <font color="blue">cell transplantation</font> for <font color="blue">breast cancer</font>, that <font color="blue">constituted</font> a     <font color="blue">significant</font> portion of the overall stem <font color="blue">cell therapy</font> market, at the time,     may have limited <font color="blue">clinical benefit</font></td>
    </tr>
    <tr>
      <td>The lack of <font color="blue">reimbursement</font> for these     <font color="blue">procedures by insurance payors</font> has <font color="blue">negatively affect</font>ed the <font color="blue">marketability</font> of     our products in this <font color="blue">indication</font> in the past</td>
    </tr>
    <tr>
      <td>Use of animal-derived materials could harm our product <font color="blue">development</font> and     <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td>Some of the <font color="blue">manufacturing</font> materials and/or <font color="blue">components</font> we use in, and are     critical  to,  our  TRC  <font color="blue">manufacturing</font>  processes  involve  the use of     animal-derived  products,  including  <font color="blue">fetal bovine serum</font></td>
    </tr>
    <tr>
      <td><font color="blue">Suppliers </font>or     <font color="blue">regulatory</font>  <font color="blue">authorities</font> may limit or restrict the <font color="blue">availability</font> of such     compounds for clinical and commercial use</td>
    </tr>
    <tr>
      <td>For example, the occurrence of     so-called “mad cow disease” in <font color="blue">New Zealand or in Australia </font>may lead to a     <font color="blue">restricted supply</font> of the <font color="blue">serum currently</font> required for the TRC <font color="blue">manufacturing</font>     process</td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">restrictions</font> on</font> these <font color="blue">compounds would impose</font> a potential     <font color="blue">competitive</font>  <font color="blue">disadvantage</font>  for  our products or prevent our ability to     <font color="blue">manufacture</font>  TRC  cell  products</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue">authorities</font> in the EU are     reviewing the <font color="blue">safety issues</font> related to the use of animal-derived materials,     which  we <font color="blue">currently use</font> in our <font color="blue">production process</font></td>
    </tr>
    <tr>
      <td>We do not know what     actions, if any, the <font color="blue">authorities</font> may take as to <font color="blue">animal derived materials</font>     specific to <font color="blue">medicinal products</font> distributed in the EU Our <font color="blue">inability</font> to     develop or obtain <font color="blue">alternative compounds would harm</font> our product <font color="blue">development</font>     and <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td>There are <font color="blue">certain limitations</font> in the supply     of certain animal-derived materials, which may lead to delays in our ability     to complete <font color="blue"><font color="blue">clinical trial</font>s</font> or <font color="blue">eventually</font> to meet the anticipated market     demand for our <font color="blue"><font color="blue">cell product</font>s</font></td>
    </tr>
    <tr>
      <td>Given our limited internal <font color="blue">manufacturing</font>, sales, marketing and <font color="blue">distribution</font>     <font color="blue">capabilities</font>,  we  need  to  develop  <font color="blue">increased internal capability</font> or     <font color="blue">collaborative relationships</font> to <font color="blue">manufacture</font>, sell, market and distribute our     products</td>
    </tr>
    <tr>
      <td>We  have  only  limited  internal  <font color="blue">manufacturing</font>, sales, marketing and     <font color="blue">distribution</font> <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>As market needs develop, we intend to establish     and operate commercial-scale <font color="blue">manufacturing</font> <font color="blue">facilities</font>, <font color="blue">which will</font> need to     <font color="blue">comply with</font> all applicable <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We expect to develop new     <font color="blue">configurations</font> of our cell <font color="blue">manufacturing</font> system for these <font color="blue">facilities</font> to     enable  processes  and  cost  efficiencies associated with large-scale     <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td><font color="blue">Establishing </font>these <font color="blue">facilities</font> will require <font color="blue">significant</font>     capital  and  expertise</td>
    </tr>
    <tr>
      <td>Any delay in <font color="blue">establishing</font>, or <font color="blue"><font color="blue">difficult</font>ies</font> in     operating, these <font color="blue">facilities</font> will limit our ability to meet the anticipated     <font color="blue">market demand</font> for our <font color="blue"><font color="blue">cell product</font>s</font></td>
    </tr>
    <tr>
      <td>We intend to get assistance to market     our future <font color="blue"><font color="blue">cell product</font>s</font> through <font color="blue">collaborative relationships</font> with companies     with  established  sales, marketing and <font color="blue">distribution</font> <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">inability</font>  to develop and maintain those <font color="blue">relationships would limit</font> our     ability to market, sell and distribute our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to enter     into  successful,  long-term relationships could require us to develop     alternate  <font color="blue">arrangements</font>  at  a  time  when we need sales, marketing or     <font color="blue">distribution</font> <font color="blue">capabilities</font> to <font color="blue">meet existing demand</font></td>
    </tr>
    <tr>
      <td>We may market our TRCs     through our own <font color="blue">sales force</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to develop and retain a qualified     <font color="blue">sales force</font> could limit our ability to market, sell and distribute our cell     products</td>
    </tr>
    <tr>
      <td>We may not be able to raise the required capital to conduct our <font color="blue">operations</font>     and develop our products</td>
    </tr>
    <tr>
      <td>We  will require substantial <font color="blue">capital resources</font> in order to conduct our     <font color="blue">operations</font> and develop our products and cell <font color="blue">manufacturing</font> <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>We     expect that our <font color="blue">available cash</font> and <font color="blue">interest income will</font> be sufficient to     <font color="blue">finance currently</font> planned <font color="blue">activities</font> at least through the end of <font color="blue">fiscal year</font>     2007  (ending June 30, 2007)</td>
    </tr>
    <tr>
      <td>However, in order to grow and expand our     business, and to introduce our new <font color="blue">product <font color="blue">candidates</font></font> into the marketplace,     we will need to                                         17       _________________________________________________________________    [67]Table of <font color="blue">Contents       </font>raise  <font color="blue">additional</font>  funds</td>
    </tr>
    <tr>
      <td>We  will  also  need  <font color="blue">additional</font> funds or a     <font color="blue">collaborative partner</font>, or both, to finance the research and <font color="blue">development</font>     <font color="blue">activities</font> of our <font color="blue">product <font color="blue">candidates</font></font> for the expansion of <font color="blue">additional</font> cell     types</td>
    </tr>
    <tr>
      <td>Accordingly, we are continuing to pursue <font color="blue">additional</font> sources of     financing</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future capital</font> <font color="blue">requirements</font> will depend upon many factors, including:         •  <font color="blue">continued scientific</font> progress in our research, clinical and <font color="blue">development</font>     programs         •  costs and timing of conducting <font color="blue"><font color="blue">clinical trial</font>s</font> and seeking <font color="blue">regulatory</font>     approvals         •  <font color="blue">competing <font color="blue">technological</font></font> and market <font color="blue">development</font>s         •  our ability to establish <font color="blue">additional</font> <font color="blue">collaborative relationships</font>         •  the effect of <font color="blue">commercialization</font> <font color="blue">activities</font> and <font color="blue">facility expansions</font>, if     and as required       Because of our long-term funding <font color="blue">requirements</font>, we intend to access the     public or private equity markets if <font color="blue">conditions</font> are favorable to complete a     financing, even if we do not have an immediate need for <font color="blue">additional</font> capital     at that time, or whenever we require <font color="blue">additional</font> operating capital</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">additional</font> funding may not be available to <font color="blue">us on reasonable terms</font>, or at     all</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not available in the future, we may be required     to <font color="blue">further delay</font> or <font color="blue">terminate research</font> and <font color="blue">development</font> programs, curtail     <font color="blue">capital expenditures</font>, and reduce business <font color="blue">development</font> and other operating     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>The issuance of <font color="blue">additional</font> <font color="blue">common stock</font> for funding has the potential for     substantial dilution</td>
    </tr>
    <tr>
      <td>As noted above, we will need <font color="blue">additional</font> equity funding to <font color="blue">provide us with</font>     the  capital  to reach our <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>At such time, we <font color="blue">may enter into</font>     financing transactions at prices, which are at a substantial discount to     market</td>
    </tr>
    <tr>
      <td>Such an equity issuance would cause a <font color="blue">substantially</font> larger number of     shares to be outstanding and would dilute the ownership interest of existing     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Our stock price has <font color="blue">been volatile</font> and <font color="blue">future sales</font> of substantial numbers of     our shares could have an <font color="blue">adverse affect on</font> the <font color="blue">market price</font> of our shares</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of shares of our <font color="blue">common stock</font> has <font color="blue">been volatile</font>, ranging in     closing price between dlra1dtta11 and dlra3dtta49 during the <font color="blue">twelve month period</font> ended     June 30, 2006</td>
    </tr>
    <tr>
      <td>The price of our <font color="blue">common stock</font> may continue to fluctuate in     response to a number of events and factors, such as:         •  <font color="blue">clinical trial</font> results         •  the amount of our <font color="blue">cash resources</font> and our ability to obtain <font color="blue">additional</font>     funding          •   <font color="blue">announcements</font>  of  research  <font color="blue">activities</font>, business <font color="blue">development</font>s,     <font color="blue"><font color="blue">technological</font> innovations</font> or <font color="blue">new products by us</font> or our <font color="blue">competitors</font>         •  <font color="blue">entering into</font> or <font color="blue">terminating strategic relationships</font>         •  changes in <font color="blue"><font color="blue">government</font> regulation</font>         •  <font color="blue">disputes concerning patents</font> or <font color="blue">proprietary rights</font>         •  changes in our revenues or <font color="blue">expense levels</font>         •  public concern regarding the safety, efficacy or other aspects of the     products or <font color="blue">methodologies</font> we are developing          •   news  or  reports  from other stem cell, <font color="blue">cell therapy</font> or tissue     <font color="blue">engineering companies</font>         •  reports <font color="blue">by securities analysts</font>         •  status of the <font color="blue">investment</font> markets         •  concerns related to <font color="blue"><font color="blue">management</font> transitions</font>                                         18       _________________________________________________________________    [68]Table of <font color="blue">Contents       </font>  Any of these events may cause the price of our shares to fall, which may     <font color="blue">adversely</font> affect our business and financing <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>In addition, the     <font color="blue">stock market</font> in general and the <font color="blue">market price</font>s for <font color="blue">bio<font color="blue">technology</font> companies</font> in     particular have experienced <font color="blue">significant</font> volatility that often has been     unrelated to the operating performance or financial <font color="blue">conditions</font> of such     companies</td>
    </tr>
    <tr>
      <td>These <font color="blue">broad market</font> and industry fluctuations may <font color="blue">adversely</font> affect     the <font color="blue">trading price</font> of our stock, regardless of our operating performance or     prospects</td>
    </tr>
    <tr>
      <td>Our stock may be <font color="blue">delisted from</font> Nasdaq, <font color="blue">which <font color="blue">could affect</font></font> its <font color="blue">market price</font>     and liquidity</td>
    </tr>
    <tr>
      <td>We are required to <font color="blue">meet certain qualitative</font> and <font color="blue">financial tests</font> (including a     <font color="blue">minimum bid price</font> for our <font color="blue">common stock</font> of dlra1dtta00) to maintain the listing of     our <font color="blue">common stock</font> on the <font color="blue">Nasdaq Capital Market</font></td>
    </tr>
    <tr>
      <td>In May 2003 and in July 2004,     we received <font color="blue">notification from</font> Nasdaq of <font color="blue">potential delisting</font> as a result of     our stock trading below dlra1dtta00 for more than thirty <font color="blue">consecutive</font> business     days</td>
    </tr>
    <tr>
      <td>While in each case our stock price recovered within the permitted     grace periods <font color="blue">and Nasdaq </font><font color="blue">notified us</font> that we were again in full compliance,     we <font color="blue">cannot provide</font> any assurance that our <font color="blue">stock price would again recover</font>     within  the  specified  times if future closing bid prices below dlra1dtta00     triggered another <font color="blue">potential delisting</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">qualitative tests</font> we must meet     <font color="blue">address various corporate governance matters</font>, including <font color="blue">Audit Committee </font>and     Board  <font color="blue">composition</font></td>
    </tr>
    <tr>
      <td>Over  the last year, we have experienced director     <font color="blue">resignations</font>  and  are  devoting  increased  resources to Board member     <font color="blue">recruitment</font> and retention</td>
    </tr>
    <tr>
      <td>If we do not maintain <font color="blue">compliance with</font> the <font color="blue">Nasdaq     </font><font color="blue">requirements</font> within specified periods and subject to <font color="blue">permitted extensions</font>,     our <font color="blue">common stock</font> may be recommended for delisting (subject to any appeal we     would file)</td>
    </tr>
    <tr>
      <td>If our <font color="blue">common stock</font> were delisted, it could be more <font color="blue">difficult</font>     to buy or sell our <font color="blue">common stock</font> and to obtain accurate quotations, and the     price of our <font color="blue">stock <font color="blue">could suffer</font></font> a material decline</td>
    </tr>
    <tr>
      <td><font color="blue">Delisting </font>would also     impair our ability to <font color="blue">raise capital</font></td>
    </tr>
    <tr>
      <td>Failure of <font color="blue">third parties</font> to <font color="blue">manufacture</font> component parts or provide limited     source supplies, or imposition of <font color="blue">additional</font> regulation, would impair our     new product <font color="blue">development</font> and our sales <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We  rely  solely  on  <font color="blue"><font color="blue">third parties</font> such as</font> Astro, Moll and Cambrex to     <font color="blue">manufacture</font> or supply certain of our devices/<font color="blue">manufacturing</font> equipment, as     well  as  component parts and other <font color="blue">materials used</font> in the <font color="blue">cell product</font>     <font color="blue">manufacturing</font> process</td>
    </tr>
    <tr>
      <td>We would not be able to obtain <font color="blue">alternate sources</font> of     supply for many of these items on a short-term basis</td>
    </tr>
    <tr>
      <td>If any of our key     <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> or <font color="blue">suppliers fail</font> to perform their <font color="blue">respective obligations</font> or     if our supply of <font color="blue">components</font> or other materials is limited or <font color="blue">interrupted</font>, we     would  not  be  able  to conduct <font color="blue"><font color="blue">clinical trial</font>s</font> or market our product     <font color="blue">candidates</font> on a timely and cost-<font color="blue">competitive</font> basis, if at all</td>
    </tr>
    <tr>
      <td>Finally, we may not be able to continue our present <font color="blue">arrangements</font> with our     suppliers, supplement existing relationships, establish new relationships or     be able to identify and obtain the <font color="blue">ancillary materials</font> that are <font color="blue">necessary</font> to     develop our <font color="blue">product <font color="blue">candidates</font></font> in the future</td>
    </tr>
    <tr>
      <td>Our <font color="blue">dependence upon third</font>     parties for the supply and <font color="blue">manufacture</font> of these items could <font color="blue">adversely</font> affect     our ability to develop and deliver <font color="blue">commercially</font> feasible products on a     timely and <font color="blue">competitive</font> basis</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing </font>our <font color="blue"><font color="blue">cell product</font>s</font> in centralized <font color="blue">facilities</font> may increase the     risk that we will not have <font color="blue">adequate quantities</font> of our <font color="blue"><font color="blue">cell product</font>s</font> for     <font color="blue">clinical programs</font></td>
    </tr>
    <tr>
      <td>We rely on a <font color="blue">third party</font> <font color="blue"><font color="blue">manufacture</font>r</font>, Fraunhofer Institute for Interfacial     Engineering and Bio<font color="blue">technology</font> in Stuttgart, Germany, to supply of TRC-based     cell  products for certain EU <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Reliance <font color="blue">on <font color="blue">third party</font></font>     <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> entails risks including <font color="blue">regulatory</font> compliance and quality     assurance and the <font color="blue">possible breach</font> of the <font color="blue">manufacturing</font> agreement by the     <font color="blue">third party</font></td>
    </tr>
    <tr>
      <td>We are subject to similar <font color="blue">regulatory</font> and <font color="blue">compliance risks at</font>     our  site  in  Ann Arbor, Michigan</td>
    </tr>
    <tr>
      <td>Both sites are subject to ongoing,     periodic, unannounced inspection by <font color="blue">regulatory</font> agencies to <font color="blue">ensure strict</font>     <font color="blue">compliance with</font> cGMP regulations and other <font color="blue"><font color="blue">government</font>al regulations</font> and     <font color="blue">corresponding foreign standards</font></td>
    </tr>
    <tr>
      <td>Our present and future <font color="blue"><font color="blue"><font color="blue">manufacture</font>r</font>s</font> might     not be able to <font color="blue">comply with</font> these <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We do not have     redundant cell <font color="blue">manufacturing</font> sites, in the event our cell <font color="blue">manufacturing</font>     <font color="blue">facilities</font> are damaged or destroyed, our <font color="blue">clinical trial</font> programs and other     business <font color="blue">prospects would</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>19       _________________________________________________________________    [69]Table of <font color="blue">Contents       </font>If we do not keep pace with our <font color="blue">competitors</font> and <font color="blue">with <font color="blue">technological</font></font> and     market  changes, our <font color="blue">products may</font> become obsolete and our business may     suffer</td>
    </tr>
    <tr>
      <td>The  markets  for  our products are very <font color="blue">competitive</font>, subject to rapid     <font color="blue">technological</font> changes, and vary for different <font color="blue">candidates</font> and processes that     <font color="blue">directly <font color="blue">compete with</font></font> our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may have developed, or     could in the future develop, new <font color="blue">technologies</font> that <font color="blue">compete with</font> our products     or even render our <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td>As an example, in the past, published     studies have suggested that hematopoietic stem <font color="blue">cell therapy</font> use for bone     marrow transplantation, following marrow ablation due to chemotherapy, may     have limited <font color="blue">clinical benefit</font> in the treatment of <font color="blue">breast cancer</font>, which was a     <font color="blue">significant</font>  portion of the <font color="blue">overall hematopoietic stem cell transplant</font>     market</td>
    </tr>
    <tr>
      <td>This resulted in the <font color="blue">practical elimination</font> of this market for our     cell-based product for this <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>Our cell <font color="blue">manufacturing</font> system, the AastromReplicell System, is designed to     improve and automate the processes for producing <font color="blue">cells used</font> in <font color="blue">therapeutic</font>     procedures</td>
    </tr>
    <tr>
      <td>Even if we are able to <font color="blue">demonstrate improved</font> or equivalent     results,  the cost or process of treatment and other <font color="blue">factors may</font> cause     <font color="blue">researchers</font> and <font color="blue">practitioners</font> to not use our products and we <font color="blue">could suffer</font> a     <font color="blue">competitive</font> <font color="blue">disadvantage</font></td>
    </tr>
    <tr>
      <td>Finally, to the extent that others develop new     <font color="blue">technologies</font> that address the targeted <font color="blue">application</font> for our products, our     business will suffer</td>
    </tr>
    <tr>
      <td>We  have experienced <font color="blue">significant</font> <font color="blue">management</font> turnover, and if we cannot     attract and retain <font color="blue">key personnel</font>, then our business will suffer</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in large part upon our ability to attract and retain     <font color="blue">highly qualified scientific</font> and <font color="blue"><font color="blue">management</font> personnel</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face competition</font>     for <font color="blue">such personnel from</font> other companies, research and <font color="blue">academic institutions</font>     and other entities</td>
    </tr>
    <tr>
      <td>Further, in an effort to <font color="blue">conserve financial resources</font>,     we have <font color="blue">implemented reductions</font> in our work <font color="blue">force on two previous occasions</font></td>
    </tr>
    <tr>
      <td>As a result of these and other factors, we may not be successful in hiring     or retaining <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to replace any <font color="blue">key employee could</font>     harm our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">On December </font>28, 2005, we announced that we would begin a search for a new     Chief  Executive  Officer  to succeed Dr</td>
    </tr>
    <tr>
      <td>Armstrong, who announced his     intention to transition out of day-to-day <font color="blue">management</font> <font color="blue">of the Company</font></td>
    </tr>
    <tr>
      <td>On     July 17, 2006 we announced that <font color="blue">George W Dunbar </font>had joined the Company as     CEO, President and a Director, and that Dr</td>
    </tr>
    <tr>
      <td><font color="blue">Armstrong </font><font color="blue">will continue</font> in his     role  as  <font color="blue">Chairman of the Board </font>for the remainder of his term</td>
    </tr>
    <tr>
      <td>We also     announced that James A Cour, former President and COO, had left the <font color="blue">Company     </font>to pursue other <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>If our patents and <font color="blue">proprietary rights</font> do not provide substantial protection,     then our business and <font color="blue">competitive</font> position will suffer</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in large part on our ability to develop or license and     <font color="blue">protect proprietary products</font> and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>However, <font color="blue">patents may</font> not be     <font color="blue">granted on</font> any of our pending or future <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font></td>
    </tr>
    <tr>
      <td>Also, the scope     of  any  of  our issued <font color="blue">patents may</font> not be <font color="blue">sufficiently</font> broad to offer     <font color="blue">meaningful</font> protection</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">issued patents</font> or <font color="blue">patents licensed</font>     to us could be <font color="blue">successfully</font> challenged, invalidated or <font color="blue">circumvented</font> so that     our  patent  <font color="blue">rights would</font> not create an <font color="blue">effective</font> <font color="blue">competitive</font> barrier</td>
    </tr>
    <tr>
      <td>Furthermore, we rely on exclusive, world-wide licenses relating to the     production of <font color="blue">human cells granted</font> to us by the <font color="blue"><font color="blue">University of Michigan</font> </font>for     certain of our patent rights</td>
    </tr>
    <tr>
      <td>If we <font color="blue"><font color="blue">materially</font> breach such <font color="blue">agreements</font></font> or     otherwise  fail  to <font color="blue">materially</font> <font color="blue">comply with</font> such <font color="blue">agreements</font>, or if such     <font color="blue">agreements</font> expire or are <font color="blue">otherwise terminated by us</font>, we may lose our rights     under the patents held by the <font color="blue">University of Michigan</font></td>
    </tr>
    <tr>
      <td>The     first of these <font color="blue">underlying patents will</font> expire on March 21, 2012</td>
    </tr>
    <tr>
      <td>We also     <font color="blue">rely on trade secrets</font> and unpatentable know-how that we seek to protect, in     part,  by  confidentiality <font color="blue">agreements</font> with our employees, consultants,     suppliers and licensees</td>
    </tr>
    <tr>
      <td>These <font color="blue">agreements</font> may be breached, and we might not     have <font color="blue">adequate remedies</font> for any breach</td>
    </tr>
    <tr>
      <td>If this were to occur, our business     and <font color="blue">competitive</font> position would suffer</td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font><font color="blue">property litigation could harm</font> our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will also depend</font> in part on our ability to develop <font color="blue">commercially</font>     viable  products  <font color="blue">without infringing</font> the <font color="blue">proprietary rights</font> of others</td>
    </tr>
    <tr>
      <td>Although we have not been subject to any <font color="blue">filed infringement</font> claims, other     <font color="blue">patents could</font> exist or could be <font color="blue">filed <font color="blue">which would</font> prohibit</font> or limit our     ability to market our products or maintain our <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td>In the     event of an <font color="blue">intellectual property</font> dispute, we may be forced to litigate</td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font>property litigation would divert <font color="blue">management</font>’s attention from     developing our products and <font color="blue">would force us</font> to incur                                         20       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font>substantial  <font color="blue">costs regardless</font> of whether we are successful</td>
    </tr>
    <tr>
      <td>An adverse     <font color="blue">outcome could</font> subject us to <font color="blue">significant</font> liabilities to <font color="blue">third parties</font>, and     force us to curtail or cease the <font color="blue">development</font> and sale of our products and     processes</td>
    </tr>
    <tr>
      <td>The <font color="blue">government</font> maintains <font color="blue">certain rights</font> in <font color="blue">technology</font> that we develop using     <font color="blue">government</font> grant money and we may lose the revenues from such <font color="blue">technology</font> if     we do not <font color="blue">commercialize</font> and utilize the <font color="blue">technology</font> pursuant to established     <font color="blue">government</font> <font color="blue">guidelines</font></td>
    </tr>
    <tr>
      <td>Certain of our and our <font color="blue">licensors</font>’ research have been or are being funded in     part by <font color="blue">government</font> grants</td>
    </tr>
    <tr>
      <td>As a result of such funding, the US Government     has  established  <font color="blue">guidelines</font> and have <font color="blue">certain rights</font> in the <font color="blue">technology</font>     developed with the grant</td>
    </tr>
    <tr>
      <td>If we fail to meet these <font color="blue">guidelines</font>, we would lose     our <font color="blue">exclusive rights</font> to these products, and we <font color="blue">would lose potential revenue</font>     <font color="blue">derived from</font> the sale of these products</td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font><font color="blue">product <font color="blue">liability</font></font> claims <font color="blue">could affect</font> our earnings and financial     condition</td>
    </tr>
    <tr>
      <td>We face an inherent business risk of exposure to <font color="blue">product <font color="blue">liability</font></font> claims in     the event that the use of the AastromReplicell System and/or TRCs during     <font color="blue"><font color="blue">clinical trial</font>s</font>, or after <font color="blue">commercialization</font>, results in <font color="blue">adverse events</font></td>
    </tr>
    <tr>
      <td>As a     result, we may <font color="blue">incur <font color="blue">significant</font></font> <font color="blue">product <font color="blue">liability</font></font> exposure, which could     exceed existing insurance coverage</td>
    </tr>
    <tr>
      <td>We may not be able to maintain adequate     levels of insurance at reasonable cost and/or reasonable terms</td>
    </tr>
    <tr>
      <td><font color="blue">Excessive     </font><font color="blue">insurance costs</font> or uninsured claims <font color="blue">would increase</font> our operating loss and     affect our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">corporate documents</font> and Michigan <font color="blue">law contain provisions</font> that may make it     more <font color="blue">difficult</font> for us to be acquired</td>
    </tr>
    <tr>
      <td><font color="blue">Our Board of Directors </font>has the authority, without shareholder approval, to     issue  <font color="blue">additional</font>  shares  of  preferred  stock and to fix the rights,     preferences, privileges and <font color="blue">restrictions</font> of these <font color="blue">shares without</font> any further     vote or <font color="blue">action by</font> our <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>This authority, together with certain     provisions of our charter documents, may have the affect of making it more     <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire, or of <font color="blue">discouraging</font> a <font color="blue">third party</font>     <font color="blue">from attempting</font> to acquire control of our company</td>
    </tr>
    <tr>
      <td>This <font color="blue">affect could</font> occur     even if our <font color="blue">shareholders</font> consider the change in control to be in their best     interest</td>
    </tr>
    <tr>
      <td>We are required to evaluate our <font color="blue"><font color="blue">internal control</font> <font color="blue">over financial</font></font> reporting     under Section 404 of the Sarbanes-Oxley Act of 2002 and any adverse results     from such <font color="blue">evaluation</font> could have a <font color="blue">negative market reaction</font></td>
    </tr>
    <tr>
      <td><font color="blue">Pursuant to Section </font>404 of the Sarbanes-Oxley Act of 2002 (Section 404), we     are required to furnish a report by our <font color="blue">management</font> on our <font color="blue">internal control</font>     <font color="blue">over financial</font> reporting</td>
    </tr>
    <tr>
      <td>That report must contain, among other matters, an     <font color="blue">assessment</font>  of  the design and operating <font color="blue">effective</font>ness of our internal     controls <font color="blue">over financial</font> reporting as of the end of the <font color="blue">fiscal year</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">assessment</font>  must  include <font color="blue">disclosure</font> of any material <font color="blue">weaknesses</font> in our     <font color="blue"><font color="blue">internal control</font> <font color="blue">over financial</font></font> reporting identified by <font color="blue">management</font></td>
    </tr>
    <tr>
      <td><font color="blue">That     </font>report <font color="blue">must also contain</font> a statement that our <font color="blue">independent registered public</font>     <font color="blue">accounting firm</font> has issued an <font color="blue">attestation</font> report on <font color="blue">management</font>’s <font color="blue">assessment</font>     of such <font color="blue">internal control</font>s and <font color="blue">independent registered public</font> accounting     firm’s <font color="blue">assessment</font> of the design and operating <font color="blue">effective</font>ness of our system of     internal accounting controls <font color="blue">over financial</font> reporting</td>
    </tr>
    <tr>
      <td>If in the future we     are unable to assert that our <font color="blue"><font color="blue">internal control</font> <font color="blue">over financial</font></font> reporting is     <font color="blue">effective</font>  as  of  the end of the then current <font color="blue">fiscal year</font> (or, if our     <font color="blue">independent registered public</font> <font color="blue">accounting firm</font> is unable to attest that our     <font color="blue">management</font>’s  report is fairly stated or they are unable to express an     unqualified  opinion  on the design and operating <font color="blue">effective</font>ness of our     <font color="blue">internal control</font>s), we <font color="blue">could lose investor confidence</font> in the accuracy and     <font color="blue">completeness</font> of our financial reports, <font color="blue">which would</font> have a negative effect on     our stock price and our ability to <font color="blue">raise capital</font></td>
    </tr>
    <tr>
      <td>Forward-looking statements       This report contains certain forward-looking statements within the meaning     of Section 27A of the <font color="blue">Securities Act and Section </font>21E of the Securities     Exchange Act</td>
    </tr>
    <tr>
      <td>These forward-looking statements include statements regarding:         •  <font color="blue">potential strategic collaborations with others</font>                                         21       _________________________________________________________________    [71]Table of <font color="blue">Contents       </font>    •  <font color="blue">future capital</font> needs         •  adequacy of <font color="blue">existing capital</font> to support <font color="blue">operations</font> for a specified time         •  product <font color="blue">development</font> and marketing plan         •  <font color="blue">clinical trial</font> plans and anticipated results         •  <font color="blue">anticipation</font> of <font color="blue">future losses</font>         •  <font color="blue">replacement</font> of <font color="blue">manufacturing</font> sources         •  <font color="blue">commercialization</font> plans         •  <font color="blue">revenue expectations</font> and operating results       These statements are subject to risks and <font color="blue">uncertainties</font>, including those set     forth  in  this  <font color="blue">Risk Factors </font>section, and actual results <font color="blue">could differ</font>     <font color="blue">materially</font>  from  those  expressed or implied in these statements</td>
    </tr>
    <tr>
      <td>All     forward-looking statements included in this <font color="blue">registration</font> statement are made     as  of  the  date  hereof</td>
    </tr>
    <tr>
      <td>We assume <font color="blue">no obligation</font> to update any such     forward-looking statement or to update any reason why actual results might     differ</td>
    </tr>
  </tbody>
</table>